Best Healthcare Dividend Stocks for 2026

Healthcare is one of the most reliable sectors for dividend investors. Aging populations, non-discretionary spending, and deep patent moats create the kind of durable cash flows that fund decades of dividend growth. Here are the best healthcare dividend stocks to own in 2026, spanning pharma, medical devices, and managed care.

Why Healthcare Stocks Are Dividend Powerhouses

Healthcare spending in the United States exceeded $4.8 trillion in 2025, and that number is projected to grow at roughly 5% annually through the end of the decade. When people get sick, they don't stop buying medication because the economy is slowing down. That fundamental reality is what makes healthcare one of the most dependable sectors for dividend income.

Several structural forces are working in favor of healthcare dividend investors right now:

• Aging demographics: The global population aged 65 and older is expected to double by 2050. Every additional year of life expectancy translates into more prescriptions, more surgeries, and more medical device implants. This is a multi-decade tailwind that no amount of political noise can reverse.
• Recurring revenue models: Pharmaceutical companies benefit from drugs that patients take daily for years or decades. Medical device companies sell implants that require follow-up procedures and replacement parts. Insurance companies collect premiums every single month. These are not one-time transactions.
• Patent moats and regulatory barriers: FDA approval processes take years and cost billions, creating enormous barriers to entry. Once a drug is approved and established, generic competition is often delayed by patent exclusivity periods lasting a decade or more. This pricing power directly supports dividend growth.
• Global expansion: Emerging markets are rapidly growing their healthcare infrastructure. Companies with international reach can tap into new patient populations while maintaining premium pricing in developed markets.

Several of the top healthcare dividend payers are Dividend Aristocrats or even Dividend Kings, meaning they have raised their dividends for 25 or 50+ consecutive years, respectively. That kind of track record speaks for itself.

The Best Healthcare Dividend Stocks for 2026

1. Johnson & Johnson (JNJ)

Dividend Yield: ~3.0% | Consecutive Years of Increases: 62 | Sub-sector: Diversified Healthcare

JNJ is the gold standard of healthcare dividend investing. With over six decades of consecutive dividend increases, Johnson & Johnson has proven its ability to generate reliable cash flows through recessions, pandemics, and major industry shifts. Following the Kenvue consumer health spinoff, JNJ is now a more focused company built on two pillars: pharmaceuticals and medical devices.

The pharmaceutical segment is anchored by blockbuster drugs including Darzalex (multiple myeloma), Stelara (immunology), and Tremfya (psoriasis). The MedTech division holds leadership positions in orthopedics, surgical robotics, and cardiovascular devices. JNJ's AAA credit rating, one of only two companies in the world to hold that distinction, reflects the financial fortress behind the dividend.

Why own it: Unrivaled dividend consistency, a diversified revenue base, and a fortress balance sheet. JNJ is the anchor holding for any healthcare dividend portfolio. Its 5-year dividend growth rate of approximately 6% ensures your income keeps pace with inflation.

2. AbbVie (ABBV)

Dividend Yield: ~3.6% | Consecutive Years of Increases: 52* | Sub-sector: Biopharmaceuticals

ABBV has emerged as one of the most compelling income stories in pharma. Since spinning off from Abbott in 2013, AbbVie has delivered aggressive dividend growth averaging over 10% annually. The company successfully navigated the Humira patent cliff, with newer immunology drugs Skyrizi and Rinvoq now generating combined annual revenue exceeding $16 billion.

Beyond immunology, AbbVie has a growing presence in oncology (Imbruvica, Venclexta) and neuroscience (Vraylar, Qulipta). The 2020 Allergan acquisition added Botox and a robust aesthetics franchise that provides diversification away from pure pharmaceuticals. With a payout ratio hovering around 50%, the dividend has ample room to continue growing.

Why own it: Best-in-class dividend growth among large-cap pharma, a proven ability to manage patent transitions, and a deep pipeline. If you are choosing between AbbVie and Johnson & Johnson, consider our ABBV vs JNJ comparison for a detailed side-by-side analysis. Many investors choose to own both.

3. Pfizer (PFE)

Dividend Yield: ~6.2% | Consecutive Years of Increases: 14 | Sub-sector: Pharmaceuticals

PFE offers the highest yield on this list, though that elevated yield comes with context. Pfizer's stock has been under pressure as COVID-19 vaccine and Paxlovid revenues have normalized sharply from their pandemic peaks. However, the underlying business is more interesting than the headline narrative suggests.

Pfizer deployed roughly $43 billion of its COVID windfall on acquisitions, most notably the $43 billion purchase of Seagen, which instantly made Pfizer a major player in oncology. The company now has one of the deepest oncology pipelines in the industry, with key assets in breast cancer, bladder cancer, and blood cancers. Revenue from non-COVID products has been growing at a healthy clip, and management has committed to $4 billion in cost savings by 2027.

Why own it: High current yield for investors who need income now, a transformative oncology pipeline through Seagen, and a stock price that already reflects significant pessimism. The risk/reward profile is attractive for patient dividend investors willing to ride out near-term uncertainty.

4. Abbott Laboratories (ABT)

Dividend Yield: ~1.9% | Consecutive Years of Increases: 52 | Sub-sector: Medical Devices & Diagnostics

ABT is the growth engine of the healthcare dividend space. While the current yield is modest, Abbott has been compounding its dividend at roughly 12% annually over the past five years. The company's FreeStyle Libre continuous glucose monitoring system is a juggernaut, with a massive addressable market as diabetes prevalence continues to climb globally.

Abbott's four business segments (medical devices, diagnostics, nutritional products, and established pharmaceuticals) provide balanced revenue streams. The medical devices segment is the star, with leading positions in structural heart, electrophysiology, and neuromodulation alongside the Libre franchise. Management has consistently delivered above-market organic growth while maintaining a disciplined approach to capital allocation.

Why own it: Abbott is the pick for investors who prioritize dividend growth over current yield. At a 12% annual dividend growth rate, your income from ABT will double every six years. Pair it with a higher-yielding name like Pfizer or AbbVie for a balanced income and growth combination.

5. Medtronic (MDT)

Dividend Yield: ~3.3% | Consecutive Years of Increases: 47 | Sub-sector: Medical Devices

MDT is the world's largest pure-play medical device company. Its product portfolio spans cardiac rhythm management, spinal surgery, surgical robotics, diabetes devices, and neurovascular tools. The company holds top-three market share in nearly every category it competes in.

Medtronic has faced execution challenges in recent years, with product recalls and slower-than-expected launches weighing on the stock. However, the company's new Hugo robotic surgery platform and next-generation diabetes technology are beginning to contribute meaningfully to growth. With 47 consecutive years of dividend increases, Medtronic is approaching Dividend King status and management has made clear that maintaining the streak is a priority.

Why own it: Attractive yield for a device company, approaching Dividend King status, and a portfolio of category-leading products in high-growth procedural markets. Medtronic trades at a discount to its historical valuation, offering a potential re-rating catalyst alongside steady income.

6. Bristol-Myers Squibb (BMY)

Dividend Yield: ~4.5% | Consecutive Years of Increases: 17 | Sub-sector: Biopharmaceuticals

BMY is navigating one of the more complex patent cliff transitions in pharma. Blockbuster drugs Eliquis and Opdivo face patent expirations in the coming years, representing a significant revenue headwind. However, Bristol-Myers has been aggressively rebuilding through acquisitions and pipeline development.

The company's newer growth drivers include Camzyos (cardiovascular), Sotyktu (psoriasis), and Opdualag (melanoma). The acquisition pipeline has been active, with deals adding assets in neuroscience, cardiovascular, and immunology. The current yield above 4% reflects the market's concern about the patent cliff, but management has been clear about protecting the dividend through the transition period.

Why own it: High current yield and a management team with a track record of navigating patent transitions. BMY is priced for pessimism, which means investors are being paid well to wait for the pipeline to mature. Suitable for income-focused investors with a 3-5 year time horizon.

7. UnitedHealth Group (UNH)

Dividend Yield: ~1.5% | Consecutive Years of Increases: 15 | Sub-sector: Managed Care

UnitedHealth is the largest healthcare company by revenue and represents a different angle on healthcare dividends. Rather than developing drugs or devices, UNH profits from managing healthcare costs at scale. The company's Optum division (pharmacy benefits, care delivery, data analytics) has become a growth engine that complements the traditional insurance business.

While the current yield is modest, UnitedHealth has been growing its dividend at approximately 14% annually. The company's dominant market position, diversified revenue streams, and ability to pass costs through to premiums create a durable competitive advantage. Healthcare insurance enrollment tends to be sticky, providing predictable revenue regardless of economic conditions.

Why own it: Exposure to the managed care sub-sector diversifies a healthcare sleeve beyond pharma and devices. The rapid dividend growth rate and consistent earnings growth make UNH a strong total return candidate. Use our Dividend Calculator to see how a 14% annual dividend growth rate compounds over a decade.

Healthcare Sub-Sectors: Understanding the Differences

Not all healthcare stocks are created equal. Understanding the sub-sectors helps you build a diversified healthcare allocation rather than concentrating in a single area.

Pharmaceuticals (JNJ, ABBV, PFE, BMY)

Pharma companies develop and sell patented drugs. They tend to offer the highest yields in healthcare because their margins are enormous during patent exclusivity periods. The key risk is patent cliffs: when a blockbuster drug loses patent protection, generic competition can erode revenue quickly. The best pharma dividend stocks have diversified portfolios and deep pipelines to offset these expirations.

Medical Devices (ABT, MDT)

Device companies sell physical products used in medical procedures. Revenue is driven by procedure volumes, which are more stable and predictable than drug sales. Device companies typically have lower yields but stronger growth profiles. They face less binary risk than pharma companies because revenue is spread across many products rather than concentrated in a few blockbusters.

Managed Care and Insurance (UNH)

Insurance companies profit from the spread between premiums collected and claims paid. They benefit from scale and data advantages. Yields tend to be lower, but earnings growth is highly predictable. Regulatory risk is the primary concern, particularly around government-sponsored programs like Medicare Advantage.

Key Risks for Healthcare Dividend Investors

Healthcare dividends are not risk-free. Here are the factors you need to monitor:

• Patent cliffs: When a major drug loses patent protection, revenue can drop 70-90% for that product within two years. Always check when a company's top-selling drugs face generic competition. Companies like AbbVie and BMY are actively managing this risk through pipeline development and acquisitions.
• Regulatory and pricing pressure: Government negotiations on drug pricing (like the Inflation Reduction Act's Medicare provisions) can cap upside on certain products. While the impact has been manageable so far, expanded price controls remain a risk, particularly in election years.
• Pipeline failures: Late-stage clinical trial failures can wipe out billions in expected future revenue overnight. Diversified companies like JNJ are better insulated, but single-pipeline biotech companies can be devastated.
• Litigation: Product liability lawsuits (opioids, medical devices, environmental contamination) can create multi-billion-dollar liabilities. Always check for material litigation when evaluating healthcare dividend stocks.
• Currency exposure: Most large healthcare companies generate 40-60% of revenue internationally. A strengthening U.S. dollar reduces the value of foreign earnings when translated back, potentially pressuring dividend growth.

Building a Healthcare Dividend Sleeve

A well-constructed healthcare allocation should balance current yield with dividend growth and diversify across sub-sectors. Here is a model allocation for the healthcare portion of a dividend portfolio:

Model Healthcare Allocation

• Johnson & Johnson (JNJ) — 25%: Anchor holding. Diversified revenue, AAA balance sheet, 62-year dividend streak. The bedrock of the sleeve.
• AbbVie (ABBV) — 20%: High yield plus high growth. Successfully navigated the Humira cliff. Strong pipeline provides visibility on future growth.
• Abbott Laboratories (ABT) — 15%: Growth compounder. FreeStyle Libre franchise drives above-market organic growth. Lower yield, highest dividend growth rate.
• Pfizer (PFE) — 15%: Yield anchor. Highest current income. Seagen acquisition provides long-term growth runway. Accept near-term volatility for above-average income.
• Medtronic (MDT) — 10%: Device diversification. Approaching Dividend King status. Trades at a discount with multiple catalysts ahead.
• Bristol-Myers Squibb (BMY) — 10%: Contrarian income play. High yield reflects patent cliff concerns. Pipeline rebuilding is underway.
• UnitedHealth Group (UNH) — 5%: Managed care exposure. Highest earnings growth rate. Diversifies away from pharma and device concentration.

This model allocation produces a blended yield of approximately 3.2% with a weighted average dividend growth rate near 8%. At those numbers, an initial $50,000 investment in this sleeve would generate roughly $1,600 in annual dividends in year one, growing to approximately $3,450 by year ten through dividend growth alone, without reinvesting.

If you reinvest those dividends using a DRIP strategy, the compounding effect accelerates significantly. The total income stream after a decade of reinvestment could approach $4,800 annually on that same initial investment.

How Healthcare Fits Into a Full Dividend Portfolio

Healthcare should represent approximately 20-30% of a diversified dividend portfolio. It pairs well with other defensive sectors like consumer staples and utilities, while providing better growth characteristics than most other income-oriented sectors. For guidance on building a complete portfolio across all sectors, see our guide on building a safe dividend portfolio.

Many of the stocks on this list are also Dividend Aristocrats, meaning they fit naturally into a broader aristocrat-based strategy. If you are building a portfolio centered on long-term dividend growth, healthcare aristocrats like JNJ, ABT, and ABBV should be among your first picks.

Final Thoughts

Healthcare dividend stocks offer a rare combination: recession-resistant revenue, powerful long-term demographic tailwinds, and proven dividend track records measured in decades. The sector is not without risks — patent cliffs, regulatory pressure, and litigation can all create turbulence — but the structural advantages overwhelm the cyclical challenges over any meaningful time horizon.

The seven stocks profiled here span the full healthcare landscape: big pharma, biotech, medical devices, and managed care. Together, they provide diversification within the sector while delivering a blend of current income and dividend growth that is hard to match elsewhere in the market.

Start with the names you are most comfortable with, build your positions over time, and let the compounding do its work. Healthcare is not going away — and neither are the dividends these companies pay. Use our Dividend Calculator to model how your healthcare dividend income could grow over the next 5, 10, or 20 years.